Fisher Asset Management LLC Trims Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Fisher Asset Management LLC lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 15.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 396,798 shares of the life sciences company’s stock after selling 73,609 shares during the quarter. Fisher Asset Management LLC owned about 0.51% of Integra LifeSciences worth $17,281,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of IART. Raymond James & Associates increased its position in shares of Integra LifeSciences by 28.7% during the third quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock valued at $7,803,000 after buying an additional 45,554 shares during the period. Strs Ohio increased its position in shares of Integra LifeSciences by 6.9% during the third quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock valued at $1,593,000 after buying an additional 2,679 shares during the period. Advisor Partners II LLC purchased a new position in shares of Integra LifeSciences during the third quarter valued at about $241,000. Inspire Investing LLC increased its position in shares of Integra LifeSciences by 5.1% during the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after buying an additional 392 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Integra LifeSciences by 451.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company’s stock valued at $2,705,000 after buying an additional 57,993 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of IART opened at $28.89 on Monday. The firm has a fifty day simple moving average of $33.75 and a two-hundred day simple moving average of $38.44. The firm has a market cap of $2.27 billion, a PE ratio of 34.81, a P/E/G ratio of 0.87 and a beta of 1.17. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. Integra LifeSciences Holdings Co. has a 1-year low of $27.18 and a 1-year high of $51.12.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The firm had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company posted $0.94 EPS. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on IART. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Truist Financial cut their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. JMP Securities cut their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.